390 related articles for article (PubMed ID: 34607791)
1. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus.
Moyon Q; Sterlin D; Miyara M; Anna F; Mathian A; Lhote R; Ghillani-Dalbin P; Breillat P; Mudumba S; de Alba S; Cohen-Aubart F; Haroche J; Pha M; Boutin THD; Chaieb H; Flores PM; Charneau P; Gorochov G; Amoura Z
Ann Rheum Dis; 2022 Apr; 81(4):575-583. PubMed ID: 34607791
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination.
Izmirly PM; Kim MY; Samanovic M; Fernandez-Ruiz R; Ohana S; Deonaraine KK; Engel AJ; Masson M; Xie X; Cornelius AR; Herati RS; Haberman RH; Scher JU; Guttmann A; Blank RB; Plotz B; Haj-Ali M; Banbury B; Stream S; Hasan G; Ho G; Rackoff P; Blazer AD; Tseng CE; Belmont HM; Saxena A; Mulligan MJ; Clancy RM; Buyon JP
Arthritis Rheumatol; 2022 Feb; 74(2):284-294. PubMed ID: 34347939
[TBL] [Abstract][Full Text] [Related]
3. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F
Front Immunol; 2021; 12():781843. PubMed ID: 34956211
[TBL] [Abstract][Full Text] [Related]
4. Impact of BNT162b2 mRNA anti-SARS-CoV-2 vaccine on interferon-alpha production by plasmacytoid dendritic cells and autoreactive T cells in patients with systemic lupus erythematosus: The COVALUS project.
Mageau A; Tchen J; Ferré VM; Nicaise-Roland P; Descamps D; Delory N; François C; Mendes C; Papo T; Goulenok T; Charles N; Sacré K
J Autoimmun; 2023 Jan; 134():102987. PubMed ID: 36563528
[TBL] [Abstract][Full Text] [Related]
5. Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with Belimumab.
Schiavoni I; Olivetta E; Natalucci F; Olivieri G; Lo Presti A; Fedele G; Stefanelli P; Ceccarelli F; Conti F
Lupus; 2023 Mar; 32(3):394-400. PubMed ID: 36607313
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of BNT162b2 vaccination in adolescents with systemic lupus erythematosus.
Piyaphanee N; Charuvanij S; Thepveera S; Toh ZQ; Licciardi PV; Pattaragarn A; Wongprompitak P; Boonnak K; Pheerapanyawaranun C; Chokephaibulkit K
Lupus; 2024 Apr; 33(5):450-461. PubMed ID: 38335115
[TBL] [Abstract][Full Text] [Related]
7. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.
Demaret J; Corroyer-Simovic B; Alidjinou EK; Goffard A; Trauet J; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Labreuche J; Sobaszek A; Hisbergues M; Puisieux F; Labalette M; Lefèvre G
Front Immunol; 2021; 12():778679. PubMed ID: 34868051
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up.
Lasagna A; Lilleri D; Agustoni F; Percivalle E; Borgetto S; Alessio N; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Secondino S; Falzoni M; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
ESMO Open; 2022 Feb; 7(1):100359. PubMed ID: 34973510
[TBL] [Abstract][Full Text] [Related]
9. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases.
Hadjadj J; Planas D; Ouedrani A; Buffier S; Delage L; Nguyen Y; Bruel T; Stolzenberg MC; Staropoli I; Ermak N; Macraigne L; Morbieu C; Henriquez S; Veyer D; Péré H; Casadevall M; Mouthon L; Rieux-Laucat F; Chatenoud L; Schwartz O; Terrier B
Ann Rheum Dis; 2022 May; 81(5):720-728. PubMed ID: 35022159
[TBL] [Abstract][Full Text] [Related]
11. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
12. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
13. A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases.
Tzioufas AG; Bakasis AD; Goules AV; Bitzogli K; Cinoku II; Chatzis LG; Argyropoulou OD; Venetsanopoulou AI; Mavrommati M; Stergiou IE; Pezoulas V; Voulgari PV; Katsimpari C; Katechis S; Gazi S; Katsifis G; Sfontouris CI; Georgountzos AI; Liossis SN; Papagoras C; Fotiadis DI; Skopouli FN; Vlachoyiannopoulos PG; Moutsopoulos HM
J Autoimmun; 2021 Dec; 125():102743. PubMed ID: 34757289
[TBL] [Abstract][Full Text] [Related]
14. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
15. Risk of disease flares after SARS-CoV-2 mRNA vaccination in patients with systemic lupus erythematosus.
Kikuchi J; Kondo Y; Kojima S; Kasai S; Sakai Y; Takeshita M; Hiramoto K; Saito S; Fukui H; Hanaoka H; Suzuki K; Kaneko Y
Immunol Med; 2024 Jun; 47(2):76-84. PubMed ID: 38189429
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
17. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups.
Ferri C; Ursini F; Gragnani L; Raimondo V; Giuggioli D; Foti R; Caminiti M; Olivo D; Cuomo G; Visentini M; Cacciapaglia F; Pellegrini R; Pigatto E; Urraro T; Naclerio C; Tavoni A; Puccetti L; Varcasia G; Cavazzana I; L'Andolina M; Ruscitti P; Vadacca M; Gigliotti P; La Gualana F; Cozzi F; Spinella A; Visalli E; Dal Bosco Y; Amato G; Masini F; Pagano Mariano G; Brittelli R; Aiello V; Caminiti R; Scorpiniti D; Rechichi G; Ferrari T; Monti M; Elia G; Franceschini F; Meliconi R; Casato M; Iannone F; Giacomelli R; Fallahi P; Santini SA; Zignego AL; Antonelli A
J Autoimmun; 2021 Dec; 125():102744. PubMed ID: 34781162
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and risk of disease flare after a three-dose regimen with SARS-CoV-2 vaccination in patients with systemic lupus erythematosus: results from the prospective cohort study COVAC-SLE.
Larsen ES; Nilsson AC; Möller S; Voss AB; Johansen IS
Clin Exp Rheumatol; 2023 Mar; 41(3):676-684. PubMed ID: 35894059
[TBL] [Abstract][Full Text] [Related]
20. Impact of methotrexate on humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis.
Shirata M; Ito I; Tanaka M; Murata K; Murakami K; Ikeda H; Oi I; Hamao N; Nishioka K; Hayashi Y; Nagao M; Hashimoto M; Ito H; Ueno H; Morinobu A; Hirai T
Clin Exp Med; 2023 Dec; 23(8):4707-4720. PubMed ID: 37582911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
